X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (215) 215
Publication (44) 44
Book Chapter (2) 2
Dissertation (2) 2
Patent (2) 2
Book Review (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (82) 82
index medicus (79) 79
female (64) 64
oncology (52) 52
ovarian cancer (39) 39
article (34) 34
adult (32) 32
middle aged (31) 31
male (29) 29
aged (25) 25
cancer (25) 25
research (24) 24
expression (21) 21
animals (18) 18
activation (16) 16
orthopedics (16) 16
ovarian neoplasms - pathology (16) 16
apoptosis (15) 15
care and treatment (14) 14
cell line, tumor (14) 14
knee (14) 14
ovarian neoplasms - drug therapy (14) 14
sport sciences (14) 14
surgery (14) 14
chemotherapy (13) 13
mice (13) 13
patients (13) 13
cells (12) 12
gene expression (12) 12
mutation (12) 12
ovarian neoplasms - metabolism (12) 12
abridged index medicus (11) 11
anterior cruciate ligament (11) 11
antineoplastic agents - therapeutic use (11) 11
metastasis (11) 11
young adult (11) 11
adolescent (10) 10
analysis (10) 10
carcinoma (10) 10
clinical trials (10) 10
inhibitor (10) 10
tumors (10) 10
aged, 80 and over (9) 9
breast cancer (9) 9
multiple myeloma (9) 9
nf-kappa-b (9) 9
outcomes (9) 9
signal transduction (9) 9
survival (9) 9
treatment outcome (9) 9
carboplatin (8) 8
cohort studies (8) 8
gene expression regulation, neoplastic (8) 8
hematology (8) 8
ovarian neoplasms - genetics (8) 8
prospective studies (8) 8
proteins (8) 8
studies (8) 8
therapy (8) 8
usage (8) 8
acl reconstruction (7) 7
anterior cruciate ligament - surgery (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
cancer therapies (7) 7
cell biology (7) 7
disease progression (7) 7
injuries (7) 7
multidisciplinary sciences (7) 7
ovarian-cancer (7) 7
prognosis (7) 7
risk factors (7) 7
skin & tissue grafts (7) 7
toxicity (7) 7
age (6) 6
child (6) 6
combination (6) 6
development and progression (6) 6
drug administration schedule (6) 6
drug therapy (6) 6
genomes (6) 6
health aspects (6) 6
i-kappa b kinase - metabolism (6) 6
immunotherapy (6) 6
knee injuries - surgery (6) 6
meniscus (6) 6
multicenter (6) 6
multiple-myeloma (6) 6
nf-kappa b - metabolism (6) 6
patient outcomes (6) 6
phosphorylation (6) 6
signal transduction - genetics (6) 6
allograft (5) 5
anterior cruciate ligament reconstruction (5) 5
antineoplastic agents - pharmacology (5) 5
arthritis (5) 5
articular cartilage (5) 5
autograft (5) 5
bevacizumab (5) 5
blotting, western (5) 5
breast-cancer (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2010, Volume 16, Issue 2, pp. 664 - 672
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2008, Volume 26, Issue 22, pp. 3709 - 3714
Journal Article
Journal Article
CANCERS, ISSN 2072-6694, 08/2019, Volume 11, Issue 8, p. 1182
The NF-kappa B signaling pathway is a master and commander in ovarian cancer (OC) that promotes chemoresistance, cancer stem cell maintenance, metastasis and... 
STEM-CELLS | ACTIVATION | ovarian cancer | MACROPHAGES | stemness | nuclear factor-kappa B | IKK-BETA | RelA | RelB | chemoresistance | ONCOLOGY | PATHWAY | THERAPEUTIC TARGET | RESISTANCE | INFLAMMATORY CYTOKINES | EXPRESSION | TLR4
Journal Article
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 07/2018, Volume 16, Issue 1, pp. 196 - 9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 6, pp. dju089 - dju089
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2017, Volume 23, Issue 6, pp. 1397 - 1406
Purpose: Our preclinical studies showed that the PARP inhibitor, olaparib, prior to carboplatin attenuated carboplatin cytotoxicity. We evaluated... 
EXCISION-REPAIR | BREAST-CANCER | ONCOLOGY | PLATINUM | SENSITIVE OVARIAN-CANCER | DNA-REPAIR | COMBINATION | MAINTENANCE THERAPY | DAMAGE | CHEMOTHERAPY | PARP INHIBITOR | Piperazines - administration & dosage | Drug-Related Side Effects and Adverse Reactions - blood | Phthalazines - pharmacokinetics | Uterine Neoplasms - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carboplatin - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions - pathology | Carboplatin - adverse effects | Neoplasm Recurrence, Local - pathology | Adult | Female | Piperazines - pharmacokinetics | DNA Adducts - blood | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Leukocytes, Mononuclear - drug effects | Phthalazines - administration & dosage | Drug Administration Schedule | Carboplatin - administration & dosage | Ovarian Neoplasms - blood | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Leukocytes, Mononuclear - pathology | Maximum Tolerated Dose | Breast Neoplasms - pathology | Uterine Neoplasms - drug therapy | Breast Neoplasms - blood | Aged | Phthalazines - adverse effects | Uterine Neoplasms - blood | Tablets | Toxicity | Cytotoxicity | Comet assay | Metastases | Platinum | Safety engineering | Deoxyribonucleic acid--DNA | Adducts | Neutropenia | Thrombocytopenia | Bioassay | Bioassays | Poly(ADP-ribose) polymerase | Pharmacology | Breast cancer | Bioavailability | Patients | Carriers | Damage detection | Experimental design | Carboplatin | DNA adducts | Intracellular | Uterine cancer | Pharmacokinetics | Cancer | Index Medicus
Journal Article